Modeling the economic value of a Chagas' disease therapeutic vaccine.

TitleModeling the economic value of a Chagas' disease therapeutic vaccine.
Publication TypeJournal Article
Year of Publication2012
AuthorsLee BY, Bacon KM, Wateska AR, Bottazzi MElena, Dumonteil E, Hotez PJ
JournalHum Vaccin Immunother
Volume8
Issue9
Pagination1293-301
Date Published2012 Sep
ISSN2164-554X
KeywordsChagas Disease, Humans, Immunotherapy, Active, Latin America
Abstract

The health burden of Chagas' disease (resulting from Trypanosoma cruzi infection) in Latin America (estimated to outweigh that of malaria by 5-fold and affect 2-6 million people in Mexico alone) has motivated development of therapeutic vaccines to prevent infection progression to severe disease. Our economic model for a Chagas' therapeutic vaccine in Mexico suggests that a vaccine would be highly cost-effective and in many cases economically dominant (providing both cost savings and health benefits) throughout a range of protection durations, severe adverse event risk, and dosing regimens and would be most likely to provide a positive return on investment if the vaccine prevented (rather than delayed) the onset of cardiomyopathy.

DOI10.4161/hv.20966
Alternate JournalHum Vaccin Immunother
PubMed ID22894964
PubMed Central IDPMC3579910
Grant List5U54GM088491-02 / GM / NIGMS NIH HHS / United States
U54 GM088491 / GM / NIGMS NIH HHS / United States
Publication Categories: